Selinexor trans-isomer

• CAT Number: I036201
• CAS Number: 1421923-86-5
• Molecular Formula: C17H11F6N7O
• Molecular Weight: 443.31
• Purity: 98%
• Synonyms: KPT-330 E-isomer; KPT330 trans isomer; E-KPT 330; Selinexor E-isomer; Selinexor trans-isomer
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: O=C(NNC1=NC=CN=C1)/C=C/N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
• InChI: InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1+
• InChIKey: DEVSOMFAQLZNKR-DAFODLJHSA-N

Selinexor trans-isomer(CAT: I036201) represents an isomeric variant of Selinexor (KPT-330), functioning as a CRM1-selective inhibitor of nuclear export. It intervenes in protein trafficking originating from the nucleus, prompting cell cycle arrest and apoptosis in mesothelioma cells. Its targeted inhibition of CRM1 imparts a crucial role in controlling nuclear-cytoplasmic transport processes, thereby impacting cellular dynamics. This compound’s ability to disrupt these intricate mechanisms highlights its potential as an anticancer agent, particularly in the context of mesothelioma, by exerting control over cellular proliferation and inducing programmed cell death.

Reference

1: Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) – a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2019 Dec 17. doi: 10.1080/13543784.2020.1706087. [Epub ahead of print] PubMed PMID: 31847605.
2: Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. [Epub ahead of print] PubMed PMID: 31831564.
3: Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2019 Dec 7. pii: S0090-8258(19)31663-4. doi: 10.1016/j.ygyno.2019.11.012. [Epub ahead of print] PubMed PMID: 31822399.
4: Peterson TJ, Orozco J, Buege M. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Ann Pharmacother. 2019 Dec 2:1060028019892643. doi: 10.1177/1060028019892643. [Epub ahead of print] PubMed PMID: 31793336.
5: Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2019 Nov 21. pii: haematol.2019.236810. doi: 10.3324/haematol.2019.236810. [Epub ahead of print] PubMed PMID: 31753931.
6: Chari A, Vogl DT, Jagannath S. Selinexor for Refractory Multiple Myeloma. Reply. N Engl J Med. 2019 Nov 14;381(20):1977-1978. doi: 10.1056/NEJMc1912625. PubMed PMID: 31722163.
7: Jhaveri KD, Wanchoo R. Selinexor for Refractory Multiple Myeloma. N Engl J Med. 2019 Nov 14;381(20):1977. doi: 10.1056/NEJMc1912625. PubMed PMID: 31722162.
8: Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2019 Oct 21. doi: 10.1158/1078-0432.CCR-19-2169. [Epub ahead of print] PubMed PMID: 31636097.
9: Depping R, von Fallois M, Landesman Y, Kosyna FK. The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells. Onco Targets Ther. 2019 Oct 11;12:8387-8399. doi: 10.2147/OTT.S213208. eCollection 2019. PubMed PMID: 31632086; PubMed Central PMCID: PMC6793465.
10: Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma. 2019 Sep 23:1-10. doi: 10.1080/10428194.2019.1665664. [Epub ahead of print] PubMed PMID: 31545113.
11: Romero D. Responses to selinexor in multiple myeloma. Nat Rev Clin Oncol. 2019 Nov;16(11):661. doi: 10.1038/s41571-019-0275-4. PubMed PMID: 31485030.
12: Stirrups R. Selinexor-dexamethasone for refractory multiple myeloma. Lancet Oncol. 2019 Oct;20(10):e560. doi: 10.1016/S1470-2045(19)30566-2. Epub 2019 Aug 30. PubMed PMID: 31477451.
13: Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. PubMed PMID: 31433920.
14: Syed YY. Selinexor: First Global Approval. Drugs. 2019 Sep;79(13):1485-1494. doi: 10.1007/s40265-019-01188-9. Review. PubMed PMID: 31429063.
15: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK544627/ PubMed PMID: 31369222.
16: Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 Aug;186(4):549-560. doi: 10.1111/bjh.15969. Epub 2019 May 24. PubMed PMID: 31124580; PubMed Central PMCID: PMC6772147.
17: Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist. 2019 Jul;24(7):887-e416. doi: 10.1634/theoncologist.2019-0231. Epub 2019 Apr 17. PubMed PMID: 30996012; PubMed Central PMCID: PMC6656474.
18: Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. Mol Cancer Ther. 2018 Dec;17(12):2564-2574. doi: 10.1158/1535-7163.MCT-17-0789-ATR. PubMed PMID: 30510142.
19: Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto C, Del Col A, Neri P, Reece D, Kauffman M, Shacham S, Unger TJ, Jeha J, Saint-Martin JR, Shah J, Chen C. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23. PubMed PMID: 30352784; PubMed Central PMCID: PMC6302280.
20: Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget. 2018 Oct 2;9(77):34567-34581. doi: 10.18632/oncotarget.26179. eCollection 2018 Oct 2. PubMed PMID: 30349650; PubMed Central PMCID: PMC6195388.